Castle Biosciences CSTL 深 滬
已收盤 02-06 16:00:00 美东时间
32.75
+0.350
+1.08%
華盛通- 最 高33.305
- 今 開32.99
- 成交量 55.65万股
- 最 低 31.635
- 昨 收 32.40
- 總市值 9.56亿
- 52周最高 44.28
- 市盈率 靜 52.52
- 換手率 1.91%
- 52周最低 14.59
- 委 比 -84.76%
- 總股本 2918.87万
- 歷史最高 107.69
- 量 比 1.10
- 振 幅 5.15%
- 歷史最低 9.2601
- 每 手 1
- 風險率 8.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
The Analyst Verdict: Castle Biosciences In The Eyes Of 7 Experts
Providing a diverse range of perspectives from bullish to bearish, 7 analysts h...
01-27 04:01
Guggenheim Maintains Buy on Castle Biosciences, Raises Price Target to $47
Guggenheim analyst Subbu Nambi maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $43 to $47.
01-27 00:33
Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares
Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares Derek J. Maetzold, President and Chief Executive Officer of Castle Biosciences Inc., reported a disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below. D
01-23 05:16
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Castle Biosciences reported strong 2025 performance, with revenue exceeding $340 million, surpassing the guided range of $327-335 million. Core revenue drivers, DecisionDx-Melanoma and TissueCypher, saw a 37% increase in total test reports compared to 2024. Year-end 2025 cash, cash equivalents, and marketable investments are expected to total approximately $300 million. The company also launched AdvanceAD-Tx in November 2025, with over 50% of gra...
01-11 21:00
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
Guggenheim Maintains Buy on Castle Biosciences, Raises Price Target to $43
Guggenheim analyst Subbu Nambi maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $30 to $43.
01-06 00:56
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Canaccord Genuity Maintains Buy on Castle Biosciences, Raises Price Target to $50
Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $37 to $50.
2025-12-22 20:48
